CoChat

The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1.

Open access

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

The senescence-associated secretory phenotype (SASP) can be provoked by side effects of therapeutic agents, fueling advanced complications including cancer resistance. However, the intracellular signal network supporting initiation and development of the SASP driven by treatment-induced damage remains unclear. Here we report that the transcription factor Zscan4 is elevated for expression by an ATM-TRAF6-TAK1 axis during the acute DNA damage response and enables a long term SASP in human stromal cells. Further, TAK1 activates p38 and PI3K/Akt/mTOR to support the persistent SASP signaling. As TAK1 is implicated in dual feedforward mechanisms to orchestrate the SASP development, pharmacologically targeting TAK1 deprives cancer cells of resistance acquired from treatment-damaged stromal cells in vitro and substantially promotes tumour regression in vivo. Together, our study reveals a novel network that links functionally critical molecules associated with the SASP development in therapeutic settings, thus opening new avenues to improve clinical outcomes and advance precision medicine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-018-04010-4

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Genotoxic treatments cause distinct gene expression in human stromal cells with remarkable Zscan4 upregulation. a Representative images of human stromal cell (PSC27) senescence, developed 7–10 d after treatment by two different classes of anticancer agents. CTRL control, NDT non DNA-damaging treatment, DTX docetaxel, PTX paclitaxel, VCR vincristine, DT DNA-damaging treatment, BLEO bleomycin, MIT mitoxantrone, and RAD radiation. Upper panel, SA-β-Gal staining; lower panel, phase contrast. Yellow arrows, cytoplasmic vacuoles. Scale bars, 15 μm. b SA-β-Gal staining statistics of cells in the individual groups of (a). Data obtained from counting of at least 200 cells per independent experiment, and analyzed using Student’s t-test. c BrdU incorporation profiles of cells in the individual groups of (a), with representative images provided on the right (CTRL/DTX/BLEO shown for example; green, BrdU; blue, DAPI). At least 200 cells counted per independent assay. Scale bars, 15 µm. Data analyzed using Student’s t-test. d Quantification of DNA damage foci (DDF). The number of DDF per cell falls into each of the 0, 1–3, 4–10, and >10 counting categories. Right, representative images (CTRL/DTX/BLEO displayed for example; red, γH2AX; blue, DAPI). At least 200 cells counted per sample. Scale bars, 15 µm. Data analyzed using two-way ANOVA. e GO analysis (cellular component, top 100 genes) of cells treated by DT and NDT agents, respectively. Color annotations shown on the right of Panther pie charts. f Heatmap depiction of top 30 human genes significantly upregulated in stromal cells after treatment by DT agents, with expression profiles generated by NDT agents shown side-by-side for parallel comparison. Numeric values in the bracket per gene refer to the expression fold change of the DT groups against the control. g Immunoblot analysis of the expression or activation of proteins including Zscan4, 53BP1, p38, p16, p21, and a subset of canonical SASP factors. Unless noted, data in all bar plots are shown as mean ± SD and representative of 3 biological replicates. * P < 0.05, ** P < 0.01, *** P < 0.001, ^ P > 0.05
Fig. 1 Genotoxic treatments cause distinct gene expression in human stromal cells with remarkable Zscan4 upregulation. a Representative images of human stromal cell (PSC27) senescence, developed 7–10 d after treatment by two different classes of anticancer agents. CTRL control, NDT non DNA-damaging treatment, DTX docetaxel, PTX paclitaxel, VCR vincristine, DT DNA-damaging treatment, BLEO bleomycin, MIT mitoxantrone, and RAD radiation. Upper panel, SA-β-Gal staining; lower panel, phase contrast. Yellow arrows, cytoplasmic vacuoles. Scale bars, 15 μm. b SA-β-Gal staining statistics of cells in the individual groups of (a). Data obtained from counting of at least 200 cells per independent experiment, and analyzed using Student’s t-test. c BrdU incorporation profiles of cells in the individual groups of (a), with representative images provided on the right (CTRL/DTX/BLEO shown for example; green, BrdU; blue, DAPI). At least 200 cells counted per independent assay. Scale bars, 15 µm. Data analyzed using Student’s t-test. d Quantification of DNA damage foci (DDF). The number of DDF per cell falls into each of the 0, 1–3, 4–10, and >10 counting categories. Right, representative images (CTRL/DTX/BLEO displayed for example; red, γH2AX; blue, DAPI). At least 200 cells counted per sample. Scale bars, 15 µm. Data analyzed using two-way ANOVA. e GO analysis (cellular component, top 100 genes) of cells treated by DT and NDT agents, respectively. Color annotations shown on the right of Panther pie charts. f Heatmap depiction of top 30 human genes significantly upregulated in stromal cells after treatment by DT agents, with expression profiles generated by NDT agents shown side-by-side for parallel comparison. Numeric values in the bracket per gene refer to the expression fold change of the DT groups against the control. g Immunoblot analysis of the expression or activation of proteins including Zscan4, 53BP1, p38, p16, p21, and a subset of canonical SASP factors. Unless noted, data in all bar plots are shown as mean ± SD and representative of 3 biological replicates. * P < 0.05, ** P < 0.01, *** P < 0.001, ^ P > 0.05CC BY · PubMed Central
Fig. 2 Zscan4 is expressed in human lung tumour stroma after chemotherapy and correlated with poor survival statistics. a Histological assessment of Zscan4 in primary tumour tissues of NSCLC patients. Arrows in the IHC image, intensive nuclear signals of Zscan4 in stroma. Scale bars, 50 µm. Cisplatin was used as a chemotherapeutic agent for the treated patient. b Pathological appraisal of stromal Zscan4 expression in NSCLC samples. Patients were individually assigned into 4 categories per IHC staining intensity of the stroma. 1, negative; 2, weak; 3, moderate; 4, strong expression. Left, statistical comparison. Right, representative images. ES, expression level. Scale bars, 50 µm. Data analyzed by two-way ANOVA. c Boxplot summary of Zscan4 transcript expression by qRT-PCR analysis upon laser capture microdissection of cells from tumour and stroma, individually from samples of 10 randomly selected patients. d Zscan4 expression at transcription level in stromal cells collected before versus after chemotherapy of the same individuals. e Kaplan–Meier analysis of NSCLC patient. Disease free survival (DFS) stratified according to Zscan4 expression. DFS represents the length (months) of period calculated from the date of NSCLC diagnosis to the point of first time disease relapse. Data compared with log-rank (Mantel–Cox) test. f Pathological correlation between Zscan4, p38, and mTOR in the stroma of NSCLC patients post treatment. Columns represent individual patients, rows different molecules. Totally 99 patients treated by chemotherapy were analyzed. Bottom, representative IHC images of Zscan4, p38 (T-180), and mTOR (S-2448), respectively. P < 0.0001 for score-score matching by two-way ANOVA. g Statistical correlation between Zscan4 and p38 scores in the 99 tumours with matching protein expression data. h Statistical correlation between Zscan4 and mTOR scores in the same group of tumours described in f. i Statistical correlation between Zscan4 and caspase 3 (cleaved) scores in the same group of tumours described in f. j Data in all bar plots are shown as mean ± SD and representative of 3 biological replicates. Data in c, d were analyzed using Student’s t-test.* P < 0.05, ** P < 0.01, *** P < 0.001, ^ P > 0.05
Fig. 2 Zscan4 is expressed in human lung tumour stroma after chemotherapy and correlated with poor survival statistics. a Histological assessment of Zscan4 in primary tumour tissues of NSCLC patients. Arrows in the IHC image, intensive nuclear signals of Zscan4 in stroma. Scale bars, 50 µm. Cisplatin was used as a chemotherapeutic agent for the treated patient. b Pathological appraisal of stromal Zscan4 expression in NSCLC samples. Patients were individually assigned into 4 categories per IHC staining intensity of the stroma. 1, negative; 2, weak; 3, moderate; 4, strong expression. Left, statistical comparison. Right, representative images. ES, expression level. Scale bars, 50 µm. Data analyzed by two-way ANOVA. c Boxplot summary of Zscan4 transcript expression by qRT-PCR analysis upon laser capture microdissection of cells from tumour and stroma, individually from samples of 10 randomly selected patients. d Zscan4 expression at transcription level in stromal cells collected before versus after chemotherapy of the same individuals. e Kaplan–Meier analysis of NSCLC patient. Disease free survival (DFS) stratified according to Zscan4 expression. DFS represents the length (months) of period calculated from the date of NSCLC diagnosis to the point of first time disease relapse. Data compared with log-rank (Mantel–Cox) test. f Pathological correlation between Zscan4, p38, and mTOR in the stroma of NSCLC patients post treatment. Columns represent individual patients, rows different molecules. Totally 99 patients treated by chemotherapy were analyzed. Bottom, representative IHC images of Zscan4, p38 (T-180), and mTOR (S-2448), respectively. P < 0.0001 for score-score matching by two-way ANOVA. g Statistical correlation between Zscan4 and p38 scores in the 99 tumours with matching protein expression data. h Statistical correlation between Zscan4 and mTOR scores in the same group of tumours described in f. i Statistical correlation between Zscan4 and caspase 3 (cleaved) scores in the same group of tumours described in f. j Data in all bar plots are shown as mean ± SD and representative of 3 biological replicates. Data in c, d were analyzed using Student’s t-test.* P < 0.05, ** P < 0.01, *** P < 0.001, ^ P > 0.05CC BY · PubMed Central
Fig. 3 Zscan4 overexpression does not change stress-induced cell phenotypes but alters SASP expression and DDR signaling. a Statistics of DDR foci in PSC27 stable sublines established via lentiviral infection and treated by bleomycin (50 µg/ml). The number of cells displaying each category of DDR foci was counted and converted into percentage per cell population. Right, representative images (red, γH2AX; blue, DAPI). At least 200 cells counted per sample. Scale bars, 10 µm. Data analyzed by two-way ANOVA. b DNA synthesis evaluation by BrdU incorporation of cell sublines assayed in a, with BrdU-positive cells calculated in percentage. Right, representative images (green, BrdU; blue, DAPI). At least 200 cells counted per sample. Scale bars, 15 µm. Data analyzed by Student’s t-test. c Cellular senescence assessment by SA-β-Gal staining of above cell sublines, with positively stained cells shown in percentage. Right, representative images. At least 200 cells counted per sample. Scale bars, 20 µm. Data analyzed by Student’s t-test. d Transcript expression of canonical SASP factors in stromal sublines treated in a, with values normalized to the vector control per factor. Data analyzed by Student’s t-test. e Left, immunoblot analysis of inducible expression of Zscan4 and activation of DDR factors including H2AX, ATM, Kap1, Chk2, and p53 in primary PSC27 cells treated by chemotherapeutic agents. DXR, doxorubicin, a supplementary genotoxic control; Right, cells were lentivirally transduced with scramble-shRNA (SCR-shRNA) or gene-specific shRNA for Zscan4 (Zscan4-shRNA), and treated by bleomycin. Cell lysates were collected at the individual time points post treatment for immunoblotting against Zscan4 expression and DDR factor activation. Data in all bar plots are shown as mean ± SD and representative of 3 representative biological replicates. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ^P > 0.05
Fig. 3 Zscan4 overexpression does not change stress-induced cell phenotypes but alters SASP expression and DDR signaling. a Statistics of DDR foci in PSC27 stable sublines established via lentiviral infection and treated by bleomycin (50 µg/ml). The number of cells displaying each category of DDR foci was counted and converted into percentage per cell population. Right, representative images (red, γH2AX; blue, DAPI). At least 200 cells counted per sample. Scale bars, 10 µm. Data analyzed by two-way ANOVA. b DNA synthesis evaluation by BrdU incorporation of cell sublines assayed in a, with BrdU-positive cells calculated in percentage. Right, representative images (green, BrdU; blue, DAPI). At least 200 cells counted per sample. Scale bars, 15 µm. Data analyzed by Student’s t-test. c Cellular senescence assessment by SA-β-Gal staining of above cell sublines, with positively stained cells shown in percentage. Right, representative images. At least 200 cells counted per sample. Scale bars, 20 µm. Data analyzed by Student’s t-test. d Transcript expression of canonical SASP factors in stromal sublines treated in a, with values normalized to the vector control per factor. Data analyzed by Student’s t-test. e Left, immunoblot analysis of inducible expression of Zscan4 and activation of DDR factors including H2AX, ATM, Kap1, Chk2, and p53 in primary PSC27 cells treated by chemotherapeutic agents. DXR, doxorubicin, a supplementary genotoxic control; Right, cells were lentivirally transduced with scramble-shRNA (SCR-shRNA) or gene-specific shRNA for Zscan4 (Zscan4-shRNA), and treated by bleomycin. Cell lysates were collected at the individual time points post treatment for immunoblotting against Zscan4 expression and DDR factor activation. Data in all bar plots are shown as mean ± SD and representative of 3 representative biological replicates. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ^P > 0.05CC BY · PubMed Central
Fig. 4 Zscan4 expression is induced by DNA damage and regulated by the ATM/TRAF6/TAK1/p65 signaling axis. a PSC27 cells were treated by bleomycin (50 μg/ml) with or without KU55933 (KU, 10 μM) in culture. Cell lysates were immunoprecipitated with anti-p-ATM, with the immunoprecipitates (IPs) analyzed with anti-p-ATM and anti-TRAF6, respectively. b PSC27 cells lentivirally infected with scramble or TRAF6-specific shRNAs were treated with bleomycin, with lysates collected at indicated time points and subject to IP and immunoblot assays. c Anti-TAK1-based IP of PSC27 cells treated with bleomycin in the presence or absence of 5Z-7 (500 nM), followed by immunoblot analysis. d Primary PSC27 cells or those stably expressing shRNA to TRAF6 were treated with bleomycin, with IPs pulled down by anti-TRAF6 and examined by immunoblots. e Cytoplasmic and nuclear protein samples from control and bleomycin-treated PSC27 cells were analyzed for TAK1 activation and NF-κB nuclear translocation. GAPDH and Histone H1, cytoplasmic and nuclear loading controls, respectively. f Chromatin immunoprecipitation (ChIP) was performed to identify potential NF-κB binding sites in Zscan4 proximal promoter. Zscan4-p1/p2/p3 denotes 3 representative genomic sites in promoter region, with known NF-κB binding sites from WNT16B, SFRP2, IL-6, and IL-8 selected as positive controls. g Zscan4 transcript expression in PSC27 cells stably expressing an NF-κB-null mutant and treated by bleomycin, mitoxantrone or radiation. Signals normalized to untreated cells. h Expression profiling of typical ASAP factors (IL-6/Timp-1) and Zscan4 in stromal cells exposed to bleomycin. Left (histograms), cells were pretreated with inhibitors of NF-κB, ATM, or TAK1 (Bay, KU or 5Z-7, respectively) before addition of bleomycin, with transcripts collected for analysis 24 h after genotoxic treatment (data normalized to untreated sample per factor set). Right (immunoblots), protein level assessment of IL-6, Timp-1, and Zscan4 24 h after cell exposure to bleomycin. GAPDH, loading control. Data in all bar plots are shown as mean ± SD and representative of 3 biological replicates. BLEO bleomycin, KU KU55933, 5Z-7 5Z-7-oxozeaenol, Bay Bay 11–7082. Data in g, h were analyzed by Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001, ^P > 0.05
Fig. 4 Zscan4 expression is induced by DNA damage and regulated by the ATM/TRAF6/TAK1/p65 signaling axis. a PSC27 cells were treated by bleomycin (50 μg/ml) with or without KU55933 (KU, 10 μM) in culture. Cell lysates were immunoprecipitated with anti-p-ATM, with the immunoprecipitates (IPs) analyzed with anti-p-ATM and anti-TRAF6, respectively. b PSC27 cells lentivirally infected with scramble or TRAF6-specific shRNAs were treated with bleomycin, with lysates collected at indicated time points and subject to IP and immunoblot assays. c Anti-TAK1-based IP of PSC27 cells treated with bleomycin in the presence or absence of 5Z-7 (500 nM), followed by immunoblot analysis. d Primary PSC27 cells or those stably expressing shRNA to TRAF6 were treated with bleomycin, with IPs pulled down by anti-TRAF6 and examined by immunoblots. e Cytoplasmic and nuclear protein samples from control and bleomycin-treated PSC27 cells were analyzed for TAK1 activation and NF-κB nuclear translocation. GAPDH and Histone H1, cytoplasmic and nuclear loading controls, respectively. f Chromatin immunoprecipitation (ChIP) was performed to identify potential NF-κB binding sites in Zscan4 proximal promoter. Zscan4-p1/p2/p3 denotes 3 representative genomic sites in promoter region, with known NF-κB binding sites from WNT16B, SFRP2, IL-6, and IL-8 selected as positive controls. g Zscan4 transcript expression in PSC27 cells stably expressing an NF-κB-null mutant and treated by bleomycin, mitoxantrone or radiation. Signals normalized to untreated cells. h Expression profiling of typical ASAP factors (IL-6/Timp-1) and Zscan4 in stromal cells exposed to bleomycin. Left (histograms), cells were pretreated with inhibitors of NF-κB, ATM, or TAK1 (Bay, KU or 5Z-7, respectively) before addition of bleomycin, with transcripts collected for analysis 24 h after genotoxic treatment (data normalized to untreated sample per factor set). Right (immunoblots), protein level assessment of IL-6, Timp-1, and Zscan4 24 h after cell exposure to bleomycin. GAPDH, loading control. Data in all bar plots are shown as mean ± SD and representative of 3 biological replicates. BLEO bleomycin, KU KU55933, 5Z-7 5Z-7-oxozeaenol, Bay Bay 11–7082. Data in g, h were analyzed by Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001, ^P > 0.05CC BY · PubMed Central
Fig. 5 TAK1 activation engages p38 but its inhibition does not influence DDR signaling. a PSC27 cells were treated with bleomycin with or without increasing concentrations of the TAK1 inhibitor 5Z-7. Cell lysates were IPed with anti-p-TAK1, and subject to in vitro kinase assay with MKK6 as a substrate. Activation of kinase p38 was analyzed, with GAPDH as a loading control. Alternatively, IL-1α (20 ng/ml) was used to stimulate cells with or without 5Z-7, with the lysates subsequently analyzed. b IL-1α was eliminated from PSC27 cells by shRNAs. TAK1/MKK6 interaction and p38 activation in the cytosol were assessed by IP in the same conditions of a. c PSC27 cells were treated by bleomycin, or 5Z-7, or both, and subject to immunofluorescence (IF) staining of γ-H2AX. DNA damage extent in stromal cells was depicted as DDR statistics by counting the number of DDR foci per cell. Right, representative images of IF staining. Green, γ-H2AX; Blue, DAPI. Scale bars, 10 μm. Data analyzed by two-way ANOVA. d Top, representative images for clonogenic assay. PSC27 cells were treated by bleomycin alone for 6 h then released until 7d later, or treated by 5Z-7 alone continuously for 7d, or treated by both agents for individual time length in culture, after which clonogenic staining was performed. Bottom, statistics of stromal cell clonogenic growth. Data analyzed by Student’s t-test. e PSC27 cells were treated with bleomycin and/or 5Z-7, and cell lysates were collected 7d after drug treatment for immunoblot analysis. JNK1 phosphorylation and IL-8 expression were used to probe TAK1 activation and SASP development, respectively. Activation of mTOR and Akt were assayed with the same set of lysates, as well. Data in all bar plots are shown as mean ± SD. All data are representative of 3 biological replicates. * P < 0.05, ** P < 0.01, *** P < 0.001
Fig. 5 TAK1 activation engages p38 but its inhibition does not influence DDR signaling. a PSC27 cells were treated with bleomycin with or without increasing concentrations of the TAK1 inhibitor 5Z-7. Cell lysates were IPed with anti-p-TAK1, and subject to in vitro kinase assay with MKK6 as a substrate. Activation of kinase p38 was analyzed, with GAPDH as a loading control. Alternatively, IL-1α (20 ng/ml) was used to stimulate cells with or without 5Z-7, with the lysates subsequently analyzed. b IL-1α was eliminated from PSC27 cells by shRNAs. TAK1/MKK6 interaction and p38 activation in the cytosol were assessed by IP in the same conditions of a. c PSC27 cells were treated by bleomycin, or 5Z-7, or both, and subject to immunofluorescence (IF) staining of γ-H2AX. DNA damage extent in stromal cells was depicted as DDR statistics by counting the number of DDR foci per cell. Right, representative images of IF staining. Green, γ-H2AX; Blue, DAPI. Scale bars, 10 μm. Data analyzed by two-way ANOVA. d Top, representative images for clonogenic assay. PSC27 cells were treated by bleomycin alone for 6 h then released until 7d later, or treated by 5Z-7 alone continuously for 7d, or treated by both agents for individual time length in culture, after which clonogenic staining was performed. Bottom, statistics of stromal cell clonogenic growth. Data analyzed by Student’s t-test. e PSC27 cells were treated with bleomycin and/or 5Z-7, and cell lysates were collected 7d after drug treatment for immunoblot analysis. JNK1 phosphorylation and IL-8 expression were used to probe TAK1 activation and SASP development, respectively. Activation of mTOR and Akt were assayed with the same set of lysates, as well. Data in all bar plots are shown as mean ± SD. All data are representative of 3 biological replicates. * P < 0.05, ** P < 0.01, *** P < 0.001CC BY · PubMed Central
Fig. 6 mTOR is activated and interacts with the IKK complex upon genotoxic treatment. a Immunoblot analysis of ATM, TAK1, Akt and mTOR activation at different time points after bleomycin treatment of PSC27 cells. Total proteins of these factors and GAPDH were loading controls. b Representative IF images for mTOR phosphorylation (S2448) in PSC27 cells treated by bleomycin with or without RAD001 (50 nM) (blue, DAPI; red, γH2AX; green, p-mTOR). Cells were stained 7d after bleomycin treatment. Scale bars, 15 μm. c Immunoblot analysis of mTOR activation and downstream substrate (S6K1/4E-BP1) phosphorylation in cells treated by bleomycin with or without RAD001. Lysates were collected 7d after initiation of treatment, the same time point for sample acquirement of following assays. d DNA synthesis assay by BrdU incorporation for cells treated in different conditions, with positive ratios displayed in percentage. Right, representative images (green, BrdU; blue, DAPI). Scale bars, 15 μm. Data analyzed by Student’s t-test. e Stromal cells were stained in culture for SA-β-Gal, with results presented as positivity ratio. Right, representative images. Scale bars, 20 μm. Data analyzed by Student’s t-test. f Immunoblot examination of NF-κB pathway in stromal cells treated by bleomycin, with or without RAD001. Cell lysates were fractionated into cytoplasmic and nuclear extracts for comparative analysis. g Cells were transfected with a reporter construct that encodes NF-κB binding sites in the promoter region of a luciferase transgene. Signals were normalized as readings of firefly/renilla ratio. Data analyzed by Student’s t-test. h Co-IP assay to determine the interaction between mTOR and IKK complex. PSC27 cells were treated with bleomycin, and cell lysates were collected 7d later for IP analysis with anti-mTOR or anti-IKKα. IgG, control. Data in all bar plots are shown as mean ± SD and representative of 3 biological replicates. *P < 0.05, **P < 0.01, ***P < 0.001, ^P > 0.05
Fig. 6 mTOR is activated and interacts with the IKK complex upon genotoxic treatment. a Immunoblot analysis of ATM, TAK1, Akt and mTOR activation at different time points after bleomycin treatment of PSC27 cells. Total proteins of these factors and GAPDH were loading controls. b Representative IF images for mTOR phosphorylation (S2448) in PSC27 cells treated by bleomycin with or without RAD001 (50 nM) (blue, DAPI; red, γH2AX; green, p-mTOR). Cells were stained 7d after bleomycin treatment. Scale bars, 15 μm. c Immunoblot analysis of mTOR activation and downstream substrate (S6K1/4E-BP1) phosphorylation in cells treated by bleomycin with or without RAD001. Lysates were collected 7d after initiation of treatment, the same time point for sample acquirement of following assays. d DNA synthesis assay by BrdU incorporation for cells treated in different conditions, with positive ratios displayed in percentage. Right, representative images (green, BrdU; blue, DAPI). Scale bars, 15 μm. Data analyzed by Student’s t-test. e Stromal cells were stained in culture for SA-β-Gal, with results presented as positivity ratio. Right, representative images. Scale bars, 20 μm. Data analyzed by Student’s t-test. f Immunoblot examination of NF-κB pathway in stromal cells treated by bleomycin, with or without RAD001. Cell lysates were fractionated into cytoplasmic and nuclear extracts for comparative analysis. g Cells were transfected with a reporter construct that encodes NF-κB binding sites in the promoter region of a luciferase transgene. Signals were normalized as readings of firefly/renilla ratio. Data analyzed by Student’s t-test. h Co-IP assay to determine the interaction between mTOR and IKK complex. PSC27 cells were treated with bleomycin, and cell lysates were collected 7d later for IP analysis with anti-mTOR or anti-IKKα. IgG, control. Data in all bar plots are shown as mean ± SD and representative of 3 biological replicates. *P < 0.05, **P < 0.01, ***P < 0.001, ^P > 0.05CC BY · PubMed Central
Fig. 7 TAK1 inhibition abrogates the SASP development and deprives cancer cells of stroma-conferred malignancy. a Heatmap profiling of stromal cell transcriptomics after treatment by bleomycin alone, or together with each of 5Z-7, SB203580 (SB), and RAD001. Cells were collected 7d after drug treatment. The SASP-associated soluble factors are selectively displayed on the top list per expression fold change. b Transcript expression assay of several SASP canonical factors. Cells were treated by bleomycin alone or co-treated by bleomycin/SASP inhibitors. Signals were normalized to untreated samples per factor. Data analyzed by Student’s t-test. c GSEA profiling with significant enrichment scores showing a SASP-specific expression signature composed of canonical soluble factors. Head-to-head comparison of differentially expressed SASP factors was performed between cells treated by bleomycin only and cells co-treated by bleomycin/SASP inhibitors. P values determined by GSEA software. d The prostate cancer (PCa) cell line PC3 was subject to treatment by mitoxantrone (MIT) while being incubated with several types of conditioned media (CM). Upper, representative images of PC3 cells upon different treatments. Arrows, apoptotic cells; arrowheads, damaged cells. Scale bars, 50 μm. Lower, viability assessment of several cell lines incubated with various types of CM and exposed to MIT at the IC50 concentration pre-determined per line. Data analyzed by Student’s t-test. e Measurement of apoptosis in culture conditions. Results were depicted in relative luminescence units (RLUs) representing signal readings proportional to caspase-3/7 activity of PC3 cells. Data analyzed by Student’s t-test. f Dose response curves (non-linear regression fit) of PC3 cells treated by PSC27-derived CM. The concentration of MIT was plotted in an exponential scale, with cell viability assessed in relative to the untreated group and calculated in percentage. Data in all bar plots are shown as mean ± SD and representative of 3 biological replicates.* P < 0.05, ** P < 0.01, *** P < 0.001. BLEO bleomycin, SB SB203580, 5Z-7 5Z-7-oxozeaenol
Fig. 7 TAK1 inhibition abrogates the SASP development and deprives cancer cells of stroma-conferred malignancy. a Heatmap profiling of stromal cell transcriptomics after treatment by bleomycin alone, or together with each of 5Z-7, SB203580 (SB), and RAD001. Cells were collected 7d after drug treatment. The SASP-associated soluble factors are selectively displayed on the top list per expression fold change. b Transcript expression assay of several SASP canonical factors. Cells were treated by bleomycin alone or co-treated by bleomycin/SASP inhibitors. Signals were normalized to untreated samples per factor. Data analyzed by Student’s t-test. c GSEA profiling with significant enrichment scores showing a SASP-specific expression signature composed of canonical soluble factors. Head-to-head comparison of differentially expressed SASP factors was performed between cells treated by bleomycin only and cells co-treated by bleomycin/SASP inhibitors. P values determined by GSEA software. d The prostate cancer (PCa) cell line PC3 was subject to treatment by mitoxantrone (MIT) while being incubated with several types of conditioned media (CM). Upper, representative images of PC3 cells upon different treatments. Arrows, apoptotic cells; arrowheads, damaged cells. Scale bars, 50 μm. Lower, viability assessment of several cell lines incubated with various types of CM and exposed to MIT at the IC50 concentration pre-determined per line. Data analyzed by Student’s t-test. e Measurement of apoptosis in culture conditions. Results were depicted in relative luminescence units (RLUs) representing signal readings proportional to caspase-3/7 activity of PC3 cells. Data analyzed by Student’s t-test. f Dose response curves (non-linear regression fit) of PC3 cells treated by PSC27-derived CM. The concentration of MIT was plotted in an exponential scale, with cell viability assessed in relative to the untreated group and calculated in percentage. Data in all bar plots are shown as mean ± SD and representative of 3 biological replicates.* P < 0.05, ** P < 0.01, *** P < 0.001. BLEO bleomycin, SB SB203580, 5Z-7 5Z-7-oxozeaenolCC BY · PubMed Central
Fig. 8 Targeting TAK1 restricts in vivo SASP and minimizes drug resistance acquired from the treatment-damaged TME. a Experimental design of severe combined immunodeficient (SCID) mouse-based in vivo studies. Two weeks after tumour implantation and stable uptake, mice received either single or combinational agents administered as metronomic treatments composed of several cycles. b Comparative statistics of tumour volumes. PC3 cells were implanted alone or with stromal cells subcutaneously to animals, which were then subject to cyclic treatments. Tumour volumes were measured at the end of an 8-week preclinical regimen. c Representative images of tumour-bearing animals in the preclinical trial. Digital signals were proportional to in vivo luciferase activities measured by an IVIS device. d Mice were sacrificed upon presence of advanced bulky diseases. Survival duration was calculated from the time of tissue recombinant injection until the day of death. Data compared with log-rank (Mantel–Cox) test. e Transcript assessment of several canonical SASP factors expressed in stromal cells isolated from PC3 tumours. Animals that had both stromal and cancer cells in the tumour foci were selected for analysis, with stromal cells acquired by LCM. f Graphical summary. DNA damage triggers an acute response of stromal cells, during which Zscan4 is expressed via the ATM-TRAF6-TAK1 axis and translocates to the nucleus. Zscan4 promotes the expression of a subset of ASAP-associated factors through NF-κB signaling, forming the first positive feedback loop. Further, TAK1 collaterally activates p38, a kinase that subsequently engages the PI3K/Akt/mTOR pathway. mTOR subsequently activates the NF-κB machinery both directly via interaction with IKKα and indirectly by promoting the translation of IL-1α, a cytokine that strengthens TAK1 phosphorylation in the chronic SASP. Together, several feedforward mechanisms favor the SASP development until its culmination in stromal cells, which confers substantial resistance on surviving cancer cells in the damaged TME and enables disease recurrence post-therapy. Data in all bar plots are shown as mean ± SD and representative of 3 biological replicates. For animal treatments, n = 10/group. Data in b, e were analyzed by Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ^P > 0.05
Fig. 8 Targeting TAK1 restricts in vivo SASP and minimizes drug resistance acquired from the treatment-damaged TME. a Experimental design of severe combined immunodeficient (SCID) mouse-based in vivo studies. Two weeks after tumour implantation and stable uptake, mice received either single or combinational agents administered as metronomic treatments composed of several cycles. b Comparative statistics of tumour volumes. PC3 cells were implanted alone or with stromal cells subcutaneously to animals, which were then subject to cyclic treatments. Tumour volumes were measured at the end of an 8-week preclinical regimen. c Representative images of tumour-bearing animals in the preclinical trial. Digital signals were proportional to in vivo luciferase activities measured by an IVIS device. d Mice were sacrificed upon presence of advanced bulky diseases. Survival duration was calculated from the time of tissue recombinant injection until the day of death. Data compared with log-rank (Mantel–Cox) test. e Transcript assessment of several canonical SASP factors expressed in stromal cells isolated from PC3 tumours. Animals that had both stromal and cancer cells in the tumour foci were selected for analysis, with stromal cells acquired by LCM. f Graphical summary. DNA damage triggers an acute response of stromal cells, during which Zscan4 is expressed via the ATM-TRAF6-TAK1 axis and translocates to the nucleus. Zscan4 promotes the expression of a subset of ASAP-associated factors through NF-κB signaling, forming the first positive feedback loop. Further, TAK1 collaterally activates p38, a kinase that subsequently engages the PI3K/Akt/mTOR pathway. mTOR subsequently activates the NF-κB machinery both directly via interaction with IKKα and indirectly by promoting the translation of IL-1α, a cytokine that strengthens TAK1 phosphorylation in the chronic SASP. Together, several feedforward mechanisms favor the SASP development until its culmination in stromal cells, which confers substantial resistance on surviving cancer cells in the damaged TME and enables disease recurrence post-therapy. Data in all bar plots are shown as mean ± SD and representative of 3 biological replicates. For animal treatments, n = 10/group. Data in b, e were analyzed by Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ^P > 0.05CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 54 references

Research works printed but not linked: 1

  1. Kuilman, T. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133, 1019–1031 (2008). · DOI · Paper page

Cited by

See all 157

Metadata

Authors
Zhang, B., Fu, D., Xu, Q., Cong, X., Wu, C., Zhong, X., Ma, Y., Lv, Z., Chen, F., Han, L., Qian, M., Chin, Y. E., Lam, E. W. F., Chiao, P., & Sun, Y.
Affiliations
  • Shanghai Jiao Tong University (CN)
  • Tongji University (CN)
  • Jilin University (CN)
  • Jiangxi Provincial Cancer Hospital (CN)
  • Imperial College London (GB)
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Sun, Yu
Venue
Nature Communications
Published
2018-04-30
Volume
9
Issue
1
Pages
1723-1723
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2804761556
Cited by
157
References
53
Citations by year
2026: 17 · 2025: 17 · 2024: 24 · 2023: 21 · 2022: 20 · 2021: 28 · 2020: 16 · 2019: 9 · 2018: 5
FWCI
9.94
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
Funders
  • U.S. Department of Defense (PC111703)
  • Cancer Research UK (12011, A12011)
  • National Institute for Health and Care Research
  • National Natural Science Foundation of China (31671425, 81302065, 81201535, 2016YFC1302400, 81472709, 81472202)
  • Chinese Academy of Sciences
  • Imperial Experimental Cancer Medicine Centre
  • Medical Research Council (MR/N012097/1)
  • National Key Research and Development Program of China (81472202, 81302065, 2016YFC1302400)
  • NIHR Imperial Biomedical Research Centre
  • DOD Prostate Cancer Research Program (PC111703)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Keywords
senescence-associated secretory phenotype, Zscan4, TAK1, ATM, TRAF6, feedforward control, DNA damage response, p38 MAPK, PI3K/AKT/mTOR pathway, stromal cells, tumor resistance, TAK1 inhibition, tumor regression
MeSH terms
Everolimus, MAP Kinase Kinase Kinase 7, Animals, Antineoplastic Agents, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Cell Line, DNA-Binding Proteins, Epithelial Cells, Female, Humans, Lactones, Lung Neoplasms, Male, Mitoxantrone, Phenotype, Prostate, Resorcinols, Transcription Factors, Zearalenone, Signal Transduction, Gene Expression Regulation, Neoplastic, Mice, SCID, Cellular Senescence, Stromal Cells, MAP Kinase Kinase Kinases, Xenograft Model Antitumor Assays, Mammary Glands, Human, Carcinoma, Ductal, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1. https://app.cochat.ai/papers/10.1038/s41467-018-04010-4
The paper
Zhang, B., Fu, D., Xu, Q., Cong, X., Wu, C., Zhong, X., Ma, Y., Lv, Z., Chen, F., Han, L., Qian, M., Chin, Y. E., Lam, E. W. F., Chiao, P., & Sun, Y. (2018). The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1. Nature Communications. https://doi.org/10.1038/s41467-018-04010-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.